Skip to content
Non-Current Assets

Deferred Tax Assets

Merck & Co. Deferred Tax Assets decreased by 127.0% to -$315M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 122.4%, from $1.41B to -$315M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows an upward trend with a 39.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryRisk
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 4, 2026

How to read this metric

An increase may indicate future tax savings, while a significant decrease might suggest a valuation allowance or utilization of benefits.

Detailed definition

Deferred tax assets represent future tax benefits arising from deductible temporary differences between the book value o...

Peer comparison

Common across large-cap pharmaceutical firms with significant R&D tax credits and global operations.

Metric ID: deferred_tax_assets

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$1.49B$1.53B$2.75B$3.07B$2.97B$2.42B$1.29B$1.44B$996M$1.02B$1.1B$922M$876M$864M$2.21B$1.41B$1.43B$1.38B$1.17B-$315M
QoQ Change+2.6%+80.0%+11.7%-3.2%-18.7%-46.5%+11.6%-30.9%+2.2%+7.8%-16.0%-5.0%-1.4%+156.3%-36.4%+1.3%-3.2%-15.6%-127.0%
YoY Change+99.7%+58.3%-53.0%-53.0%-66.5%-57.9%-15.1%-36.1%-12.0%-15.1%+101.8%+52.8%+62.9%+59.8%-47.3%-122.4%
Range-$315M$3.07B
CAGR-27.9%
Avg YoY Growth-2.7%
Median YoY Growth-15.1%
Current Streak3 quarters decline

Frequently Asked Questions

What is Merck & Co.'s deferred tax assets?
Merck & Co. (MRK) reported deferred tax assets of -$315M in Q1 2026.
How has Merck & Co.'s deferred tax assets changed year-over-year?
Merck & Co.'s deferred tax assets decreased by 122.4% year-over-year, from $1.41B to -$315M.
What is the long-term trend for Merck & Co.'s deferred tax assets?
Over 5 years (2020 to 2025), Merck & Co.'s deferred tax assets has grown at a 39.2% compound annual growth rate (CAGR), from $223M to $1.17B.
What does deferred tax assets mean?
The value of future tax savings the company expects to realize due to accounting differences.